Clinical Trial Update: 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the combination of tanespimycin (17-allylamino-17-demethoxygeldanamycin) and bortezomib in relapsed or refractory hematologic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Diffuse Large B-cell Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Malt
• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• tanespimycin (17-N-allylamino-17-demethoxygeldanamycin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 1 | Status: TERMINATED